Advances in Systemic SiRNA Delivery

Overview

Journal Drugs Future

Publisher Thomson Reuters

Specialty Pharmacology

Date 2010 Feb 18

PMID 20161621

Citations 24

Authors

Qixin Leng

Martin C Woodle

Patrick Y Lu

A James Mixson

Affiliations

Soon will be listed here.

Abstract

Sequence-specific gene silencing with small interfering RNA (siRNA) has transformed basic science research, and the efficacy of siRNA therapeutics toward a variety of diseases is now being evaluated in pre-clinical and clinical trials. Despite its potential value, the highly negatively charged siRNA has the classic delivery problem of requiring transport across cell membranes to the cytosol. Consequently, carrier development for siRNA delivery is one of the most important problems to solve before siRNA can achieve widespread clinical use. An assortment of non-viral carriers including liposomes, peptides, polymers, and aptamers are being evaluated for their ability to shepherd siRNA to the target tissue and cross the plasma membrane barrier into the cell. Several promising carriers with low toxicity and increased specificity for disease targets have emerged for siRNA-based therapeutics. This review will discuss non-viral approaches for siRNA therapeutics, with particular focus on synthetic carriers for in vivo systemic delivery of siRNA.

Citing Articles

Fusogenic peptide delivery of bioactive siRNAs targeting CSNK2A1 for treatment of ovarian cancer.

Samec T, Alatise K, Boulos J, Gilmore S, Hazelton A, Coffin C Mol Ther Nucleic Acids. 2022; 30:95-111.

PMID: 36213692 PMC: 9530961. DOI: 10.1016/j.omtn.2022.09.012.

Non-Viral Vectors for Delivery of Nucleic Acid Therapies for Cancer.

Kanvinde S, Kulkarni T, Deodhar S, Bhattacharya D, Dasgupta A BioTech (Basel). 2022; 11(1).

PMID: 35822814 PMC: 9245904. DOI: 10.3390/biotech11010006.

Ran GTPase: A Key Player in Tumor Progression and Metastasis.

Boudhraa Z, Carmona E, Provencher D, Mes-Masson A Front Cell Dev Biol. 2020; 8:345.

PMID: 32528950 PMC: 7264121. DOI: 10.3389/fcell.2020.00345.

Development of a Biocompatible Copolymer Nanocomplex to Deliver VEGF siRNA for Triple Negative Breast Cancer.

Zhao Z, Li Y, Shukla R, Liu H, Jain A, Barve A Theranostics. 2019; 9(15):4508-4524.

PMID: 31285776 PMC: 6599648. DOI: 10.7150/thno.34314.

Lipopeptide Delivery of siRNA to the Central Nervous System.

Zabel M, Mollnow L, Bender H Methods Mol Biol. 2019; 1943:389-403.

PMID: 30838631 PMC: 6684241. DOI: 10.1007/978-1-4939-9092-4_26.

References

Kobayashi N, Nishikawa M, Hirata K, Takakura Y . Hydrodynamics-based procedure involves transient hyperpermeability in the hepatic cellular membrane: implication of a nonspecific process in efficient intracellular gene delivery. J Gene Med. 2004; 6(5):584-92. DOI: 10.1002/jgm.541. View

Console S, Marty C, Garcia-Echeverria C, Schwendener R, Ballmer-Hofer K . Antennapedia and HIV transactivator of transcription (TAT) "protein transduction domains" promote endocytosis of high molecular weight cargo upon binding to cell surface glycosaminoglycans. J Biol Chem. 2003; 278(37):35109-14. DOI: 10.1074/jbc.M301726200. View

Querbes W, Ge P, Zhang W, Fan Y, Costigan J, Charisse K . Direct CNS delivery of siRNA mediates robust silencing in oligodendrocytes. Oligonucleotides. 2008; 19(1):23-29. DOI: 10.1089/oli.2008.0165. View

RYSER H . Studies on protein uptake by isolated tumor cells. 3. Apparent stimulations due to pH, hypertonicity, polycations, or dehydration and their relation to the enhanced penetration of infectious nucleic acids. J Cell Biol. 1967; 32(3):737-50. PMC: 2107262. DOI: 10.1083/jcb.32.3.737. View

Matsui H, Tomizawa K, Lu Y, Matsushita M . Protein Therapy: in vivo protein transduction by polyarginine (11R) PTD and subcellular targeting delivery. Curr Protein Pept Sci. 2003; 4(2):151-7. DOI: 10.2174/1389203033487270. View

Meade B, Dowdy S . Enhancing the cellular uptake of siRNA duplexes following noncovalent packaging with protein transduction domain peptides. Adv Drug Deliv Rev. 2007; 60(4-5):530-6. PMC: 2293332. DOI: 10.1016/j.addr.2007.10.004. View

Toncheva V, Wolfert M, Dash P, Oupicky D, Ulbrich K, Seymour L . Novel vectors for gene delivery formed by self-assembly of DNA with poly(L-lysine) grafted with hydrophilic polymers. Biochim Biophys Acta. 1998; 1380(3):354-68. DOI: 10.1016/s0304-4165(98)00004-x. View

Lorenz C, Hadwiger P, John M, Vornlocher H, Unverzagt C . Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett. 2004; 14(19):4975-7. DOI: 10.1016/j.bmcl.2004.07.018. View

Zhou J, Wu J, Hafdi N, Behr J, Erbacher P, Peng L . PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun (Camb). 2006; (22):2362-4. DOI: 10.1039/b601381c. View

10.

Plank C, Mechtler K, Szoka Jr F, Wagner E . Activation of the complement system by synthetic DNA complexes: a potential barrier for intravenous gene delivery. Hum Gene Ther. 1996; 7(12):1437-46. DOI: 10.1089/hum.1996.7.12-1437. View

11.

Walther J, Bartlett D, Chew W, ROBERTSON C, Hostetter T, Meyer T . Downloadable computer models for renal replacement therapy. Kidney Int. 2006; 69(6):1056-63. DOI: 10.1038/sj.ki.5000196. View

12.

Mu P, Nagahara S, Makita N, Tarumi Y, Kadomatsu K, Takei Y . Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer. Int J Cancer. 2009; 125(12):2978-90. DOI: 10.1002/ijc.24382. View

13.

Meyer M, Dohmen C, Philipp A, Kiener D, Maiwald G, Scheu C . Synthesis and biological evaluation of a bioresponsive and endosomolytic siRNA-polymer conjugate. Mol Pharm. 2009; 6(3):752-62. DOI: 10.1021/mp9000124. View

14.

Snove Jr O, Rossi J . Chemical modifications rescue off-target effects of RNAi. ACS Chem Biol. 2006; 1(5):274-6. DOI: 10.1021/cb6002256. View

15.

Waite C, Sparks S, Uhrich K, Roth C . Acetylation of PAMAM dendrimers for cellular delivery of siRNA. BMC Biotechnol. 2009; 9:38. PMC: 2679008. DOI: 10.1186/1472-6750-9-38. View

16.

Robbins M, Judge A, Liang L, McClintock K, Yaworski E, MacLachlan I . 2'-O-methyl-modified RNAs act as TLR7 antagonists. Mol Ther. 2007; 15(9):1663-9. DOI: 10.1038/sj.mt.6300240. View

17.

Komarov P, Komarova E, Kondratov R, Coon J, Chernov M, Gudkov A . A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 1999; 285(5434):1733-7. DOI: 10.1126/science.285.5434.1733. View

18.

Hammond S, Bernstein E, Beach D, Hannon G . An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature. 2000; 404(6775):293-6. DOI: 10.1038/35005107. View

19.

Dobrovolskaia M, Clogston J, Neun B, Hall J, Patri A, McNeil S . Method for analysis of nanoparticle hemolytic properties in vitro. Nano Lett. 2008; 8(8):2180-7. PMC: 2613576. DOI: 10.1021/nl0805615. View

20.

Chu T, Twu K, Ellington A, Levy M . Aptamer mediated siRNA delivery. Nucleic Acids Res. 2006; 34(10):e73. PMC: 1474074. DOI: 10.1093/nar/gkl388. View